Sio Gene Therapies Inc
SIOX
Get informed when a big investor buys or sells
+ FollowMarket Cap$0
Close$
Share Statistics
| Market cap | $0.00 |
|---|---|
| Enterprise Value | $-46,127,000.00 |
| Dividend Yield | $0.43 (-) |
| Earnings per Share | $-0.98 |
| Beta | 1.09 |
| Outstanding Shares | 73,975,196 |
Return
| Return on Equity | -62.42% |
|---|---|
| Return on Assets | -59.58% |
| Return on Invested Capital | -65.55% |
Valuation & Multiples
| P/E Ratio | -0.49 |
|---|---|
| PEG | 0.56 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 1.56 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sio Gene Therapies Inc
38 employees
CEO: Pavan Cheruvu Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Its current pipeline of clinical-stage candidates includes the first potentially cur...